Opus Genetics, Inc. (IRD) Stock

Opus Genetics, Inc. (IRD) is a Healthcare stock trading at $4.04 (as of 2026-08-21), with a market capitalization of $336.11M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing and commercializing treatments for unmet needs in patients with refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution for reversal of mydriasis, a Phase III program for presbyopia and dim light/night vision disturbances, and retinal product candidates such as APX3330 plus earlier-stage candidates APX2009 and APX2014.

Understand Opus Genetics, Inc.: how it makes money

Opus Genetics develops and commercializes ophthalmic biopharmaceutical therapies for refractive and retinal eye disorders, with products like Phentolamine Ophthalmic Solution (for reversal of mydriasis) and pipeline candidates such as APX3330, and it can earn money through license and collaboration revenue.

With reported revenue of 0 in the latest quarter, the profit model is primarily dependent on clinical-stage progress and any future license and collaboration revenue rather than current operating sales.

Revenue by segment (latest quarter)
LicCollab$0.0B

Business quality (Weak): Clinical pipeline focus (including Phase III work) with an existing commercial product, but recent results show no reported revenue and very large operating losses, making outcomes and monetization timing central.

Bull case

  • Phase III execution for ophthalmic indications: The company is in Phase III clinical trials for presbyopia and dim light or night vision disturbances, which can be a key step toward potential product value.
  • Pipeline evidence through prior clinical development: Its lead retinal product candidate, APX3330, has completed Phase II clinical trial work for the treatment of diabetic retinop.
  • At least one marketed therapy in its specialty area: Opus Genetics offers Phentolamine Ophthalmic Solution for reversal of mydriasis.

Bear case

  • No reported revenue in the latest quarter: For the period ending 2026-03-31, revenue is reported as 0.0B, indicating limited or no monetization captured in that period.
  • Very large operating losses: The latest-quarter operating margin is -665.9, reflecting substantial operating loss risk while development continues.
  • Binary clinical outcome risk: Even with Phase III enrollment, the future of key therapies depends on trial results and timelines, which can shift value materially.
Valuation — source: SEC EDGAR (first-party)
Price$4.04
Market Cap$336.11M
Price / Sales41.25
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$14.20M
Net Margin-349.3%
Revenue Growth (YoY)29.1%
EPS Growth (YoY)-62.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.56 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCaligan Partners LP ($27.64M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGeorge Magrath
Employees18
CountryUS
IPO Date2015-01-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Perspective Therapeutics, Inc. (CATX)
  • Galectin Therapeutics Inc. (GALT)
  • Capricor Therapeutics, Inc. (CAPR)
  • DiaMedica Therapeutics Inc. (DMAC)
  • Abeona Therapeutics Inc. (ABEO)
  • Immuneering Corporation (IMRX)
  • Vanda Pharmaceuticals Inc. (VNDA)
  • Rockwell Medical, Inc. (RMTI)
IRD earnings history · IRD institutional & insider holders · IRD KPIs & operating metrics · IRD financials · IRD investor presentations & press releases · IRD SEC filings · IRD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.